Clin2
NCT07517198Likely a fitRecruiting

EXS74539 Study for Advanced Solid Tumors

Solid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine CancerSmall Cell Carcinomas of Non-lung OriginNon-small Cell Lung Cancer (NSCLC)Prostate CancerOvarian CancerRenal Carcinoma (Clear and Non-clear Cell)

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
40 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have a confirmed diagnosis of one of these cancers: small cell lung cancer, neuroendocrine cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, kidney cancer, head and neck cancer, liver cancer, stomach cancer, or triple-negative breast cancer
  • Your cancer has progressed or come back after at least one standard treatment, or you were unable to tolerate a previous treatment
  • You have measurable disease that can be tracked on imaging scans
  • You are in good enough health to tolerate the study (ECOG performance status 0–1, meaning you can care for yourself or mostly do light activities)
  • You do not have uncontrolled brain or spinal cord metastases (cancer spread to the brain or spinal cord)
  • You have no active serious infection and have not had major surgery in the past 4 weeks

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05985655Recruiting· Phase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors

This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

Los Angeles, California
NCT07003321Recruiting· Phase 2
Testing HRS-4508 for advanced non-small cell lung cancer

This trial tests an experimental drug called HRS-4508 for people with advanced non-small cell lung cancer that has stopped responding to standard treatments or cannot tolerate them. The goal is to see if it can shrink tumors or slow cancer growth.

Shanghai, Shanghai Municipality
NCT06395519Recruiting· Phase 1/Phase 2
Study of ETX-19477 for advanced solid tumors

This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).

Phoenix, Arizona
NCT07739966Not yet recruiting· Phase 1/Phase 2
Study of DS-3939a for advanced solid tumors

This trial tests a new drug called DS-3939a for people with advanced solid tumors, especially a type of lung cancer. The drug targets a protein on cancer cells to try to shrink tumors or slow their growth.

NCT06245122Recruiting· Phase 1
Study of CS23546 for advanced tumors

This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.

Guangzhou
NCT06944444Recruiting· Phase 1
Testing a new drug for advanced tumors

This trial tests a new drug, SSS59, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it affects the body.

Shanghai, Shanghai Municipality

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.